Onconova Therapeutics (NASDAQ:ONTX) Earning Favorable News Coverage, Analysis Shows

Press coverage about Onconova Therapeutics (NASDAQ:ONTX) has been trending positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Onconova Therapeutics earned a media sentiment score of 0.28 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 46.7942329131881 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

These are some of the news articles that may have effected Accern Sentiment’s scoring:

A number of equities analysts have recently issued reports on the company. Maxim Group reissued a “buy” rating and set a $6.00 price target on shares of Onconova Therapeutics in a research report on Thursday, November 2nd. HC Wainwright began coverage on Onconova Therapeutics in a research report on Monday, October 9th. They set a “buy” rating and a $6.00 price target on the stock. Finally, ValuEngine raised Onconova Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $7.33.

Onconova Therapeutics (NASDAQ:ONTX) traded down $0.03 during trading on Wednesday, reaching $1.48. The company’s stock had a trading volume of 101,174 shares, compared to its average volume of 130,933. Onconova Therapeutics has a 52 week low of $1.46 and a 52 week high of $3.88.

Onconova Therapeutics (NASDAQ:ONTX) last announced its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.73) by $0.02. Onconova Therapeutics had a negative return on equity of 558.97% and a negative net margin of 2,855.94%. The firm had revenue of $0.11 million during the quarter, compared to analysts’ expectations of $0.29 million. equities research analysts predict that Onconova Therapeutics will post -2.82 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Onconova Therapeutics (NASDAQ:ONTX) Earning Favorable News Coverage, Analysis Shows” was originally posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://ledgergazette.com/2017/12/07/onconova-therapeutics-ontx-earns-daily-news-sentiment-rating-of-0-28.html.

About Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells.

Insider Buying and Selling by Quarter for Onconova Therapeutics (NASDAQ:ONTX)

Receive News & Ratings for Onconova Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconova Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply